Education
About Us
Working with TipRanks
Follow Us
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
2171 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.48 - HK$19.78
Previous CloseN/A
Volume4.65M
Average Volume (3M)3.56M
Market Cap
HK$8.47B
Enterprise ValueHK$3.87B
Total Cash (Recent Filing)-¥98.44M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 26, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding572,546,700
10 Day Avg. Volume2,174,350
30 Day Avg. Volume3,559,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)286.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.96Price Target Upside-40.19% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
---
CARsgen Therapeutics Holdings Ltd. News
PremiumCompany Announcements
CARsgen Therapeutics Grants Options to Boost Employee Engagement
PremiumCompany Announcements
CARsgen Therapeutics Announces 2025 Annual General Meeting AgendaPremiumCompany Announcements
CARsgen’s Satri-cel Research Accepted for ASCO 2025 PresentationPremiumCompany Announcements
CARsgen Therapeutics Reports 2024 Financial Results with Increased Net Loss
PremiumCompany Announcements
CARsgen Reports Positive Trial Results for Cancer TherapyPremiumCompany Announcements
CARsgen Strengthens Financial Oversight with New Audit Committee---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.75%
Mutual Funds
― Other Institutional Investors
96.59% Public Companies and
Individual Investors
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$2.48 and its highest was HK$19.78 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$8.47B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Aug 26, 2025 which is in 123 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Mar 18, 2025. The company reported -HK$0.861 earnings per share for the quarter, missing the consensus estimate of -HK$0.425 by -HK$0.436.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Overvalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.43.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 572,546,700 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.861 in its last earnings report, missing expectations of -HK$0.425. Following the earnings report the stock price went down -3.93%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
---
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
HK$8.96 (-40.19% Downside)
HK$8.96 (-40.19% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
219.40%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
-28.36%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
---
2171 Stock 12 Month Forecast
Average Price Target
HK$8.96
▼(-40.19% Downside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Peijia Medical Ltd.
―
CanSino Biologics, Inc. Class H
―
Best Analysts Covering 2171
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-32.90%
downgraded a sell rating 3 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -32.90% per trade.
---